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Background
Anaemia is a common adverse event during treatment for
HCV infection. HEP3002 is an ongoing, open-label, early
access program of telaprevir in 16 countries, for patients
with genotype 1 hepatitis C with severe fibrosis or com-
pensated cirrhosis. This analysis is of the data from the
209 Romanian patients, evaluated after 16 weeks of
treatment.
Method
Liver biopsy or non-invasive tests showing severe fibrosis
or cirrhosis were required at entry. 209 patients from
Romania were treated with telaprevir in combination
with peginterferon alfa and ribavirin (PR) for 12 weeks,
followed by PR for 12 or 36 weeks. Use of iron supple-
ments, erythropoietin (EPO) and blood transfusions was
permitted. Anaemia included the clinically significant
adverse event terms of anaemia or haemoglobin (Hb)
reduction. All analyses were on the Intent to Treat (ITT)
population, using 16 week data.
Results
Mean age was 52 years; 47% were male and 100% Cauca-
sian, 59% had HCV RNA levels ≥800,000 IU/mL, 58%/42%
had severe fibrosis/cirrhosis, and 2% had genotype 1a. Up
to week 16, 57% of patients developed grade 1-4 anaemia,
with 41% Grade 3-4 cases (3% grade 4); 72 patients (34%)
dose-reduced ribavirin, and 1 (<1%) discontinued treat-
ment for anaemia. Results are shown in Table 1.
Up to week 16, 46% of patients developed grade 3 or 4
adverse events including 5 patients (2%) who developed
grade 3 or 4 rash; 9% of patients had serious adverse
events. Nine patients (4%) discontinued TVR due to
adverse events, including 6 patients (3%) who discontinued
due to rash. No deaths occurred during the study.
Conclusion
In this telaprevir early access program for patients with
severe fibrosis or compensated cirrhosis, Grade 3 or 4
anaemia was reported in 41% of patients, but discontinua-
tion for anaemia was rare (<1%). Anaemia was principally
managed by ribavirin dose reduction.
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Table 1
Type of anaemia Definition Total
(n=209)
Grade 1-2 Hb 9-10.9 or 2.5-4.4 g/dL
decrease
33 (16%)
Grade 3-4 Hb <8.9 or >4.5 g/dL
decrease
86 (41%)
D/C for anaemia 1 (<1%)
Anaemia as Serious AE 9 (4%)
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